Overview

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

Status:
Completed

Trial end date:
2018-03-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan and angiogenesis inhibitors).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Antibodies, Monoclonal
Panitumumab
Trifluridine